Table 1.

Preclinical Approaches

Approach	Mechanism of action	references
Glycogen Synthase Kinase3 Inhibitors
SB216763, CHIR98014	Reduces tau phosphorylation	[12]
SRN-003-556	Reducse soluble phosphorylated and aggregated tau	[12]
Lithium	Reduces tau pathology	[14]
Valproate	Reduces tau pathology	[15]
Other inhibitors
HSP90	Inhibition of tau degredation	[12]
Active immunization
Tau 379-408[P-Ser396-404]	Reduces tau pathology and improves cognitive tasks	[21]
Tau195-231[P202/205] Tau207-220[P212/214] Tau224-238[P231]	Significant decrease of tau pathology with increase of the microglia burden	[24]
Y10A peptide [Ser422]	Reduces tau pathology and	[25]
pBri	Reduces tau related pathology	[30]
Passive immunization
PHF-1 Antibody	Decreases tau pathology and functional impairments	[26]
PHF-1 and MC1	Decreases tau pathology with improvement of locomotor activity	[27]
DA31,MC1,PHF-1	Reduction of tau pathology	[28]
Anti-tau oligomers	Reduces hyperphosphorylated tau and blocks tau aggregation	[29]